The new serotonin receptor model (5-HT 2A) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules. DENVER, Jan. 10, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental…


Previous articleStephen Hurst Resigns from MindMed Board of Directors
Next articlePsychedelic Research and Clinical Trials in 2021